Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Protein and Glycan Mimicry in HIV Vaccine Design.

Seabright GE, Doores KJ, Burton DR, Crispin M.

J Mol Biol. 2019 May 31;431(12):2223-2247. doi: 10.1016/j.jmb.2019.04.016. Epub 2019 Apr 24. Review.

2.

A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus.

Allen ER, Krumm SA, Raghwani J, Halldorsson S, Elliott A, Graham VA, Koudriakova E, Harlos K, Wright D, Warimwe GM, Brennan B, Huiskonen JT, Dowall SD, Elliott RM, Pybus OG, Burton DR, Hewson R, Doores KJ, Bowden TA.

Cell Rep. 2018 Dec 26;25(13):3750-3758.e4. doi: 10.1016/j.celrep.2018.12.001.

3.

Targeting Glycans on Human Pathogens for Vaccine Design.

Krumm SA, Doores KJ.

Curr Top Microbiol Immunol. 2018 Jul 26. doi: 10.1007/82_2018_103. [Epub ahead of print]

PMID:
30046985
4.

Harnessing post-translational modifications for next-generation HIV immunogens.

Allen JD, Sanders RW, Doores KJ, Crispin M.

Biochem Soc Trans. 2018 Jun 19;46(3):691-698. doi: 10.1042/BST20170394. Epub 2018 May 21. Review.

5.

Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding.

Watanabe Y, Vasiljevic S, Allen JD, Seabright GE, Duyvesteyn HME, Doores KJ, Crispin M, Struwe WB.

Anal Chem. 2018 Jun 19;90(12):7325-7331. doi: 10.1021/acs.analchem.8b00573. Epub 2018 May 25.

6.

Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization.

Zeltina A, Krumm SA, Sahin M, Struwe WB, Harlos K, Nunberg JH, Crispin M, Pinschewer DD, Doores KJ, Bowden TA.

Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7031-7036. doi: 10.1073/pnas.1702127114. Epub 2017 Jun 19.

7.

The Tetrameric Plant Lectin BanLec Neutralizes HIV through Bidentate Binding to Specific Viral Glycans.

Hopper JTS, Ambrose S, Grant OC, Krumm SA, Allison TM, Degiacomi MT, Tully MD, Pritchard LK, Ozorowski G, Ward AB, Crispin M, Doores KJ, Woods RJ, Benesch JLP, Robinson CV, Struwe WB.

Structure. 2017 May 2;25(5):773-782.e5. doi: 10.1016/j.str.2017.03.015. Epub 2017 Apr 20.

8.

HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.

Coss KP, Vasiljevic S, Pritchard LK, Krumm SA, Glaze M, Madzorera S, Moore PL, Crispin M, Doores KJ.

J Virol. 2016 Nov 28;90(24):11132-11144. Print 2016 Dec 15.

9.

Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein.

Behrens AJ, Vasiljevic S, Pritchard LK, Harvey DJ, Andev RS, Krumm SA, Struwe WB, Cupo A, Kumar A, Zitzmann N, Seabright GE, Kramer HB, Spencer DI, Royle L, Lee JH, Klasse PJ, Burton DR, Wilson IA, Ward AB, Sanders RW, Moore JP, Doores KJ, Crispin M.

Cell Rep. 2016 Mar 22;14(11):2695-706. doi: 10.1016/j.celrep.2016.02.058. Epub 2016 Mar 10.

10.

Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies.

Krumm SA, Mohammed H, Le KM, Crispin M, Wrin T, Poignard P, Burton DR, Doores KJ.

Retrovirology. 2016 Feb 2;13:8. doi: 10.1186/s12977-016-0241-5.

11.

The HIV glycan shield as a target for broadly neutralizing antibodies.

Doores KJ.

FEBS J. 2015 Dec;282(24):4679-91. doi: 10.1111/febs.13530. Epub 2015 Oct 23. Review.

12.

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies.

McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, van Gils MJ, Euler Z, Burger JA, Seaman MS, Sanders RW, Schuitemaker H, Poignard P, Wrin T, Burton DR.

PLoS Pathog. 2015 Aug 12;11(8):e1005110. doi: 10.1371/journal.ppat.1005110. eCollection 2015 Aug.

13.

Determination of N-linked Glycosylation in Viral Glycoproteins by Negative Ion Mass Spectrometry and Ion Mobility.

Bitto D, Harvey DJ, Halldorsson S, Doores KJ, Pritchard LK, Huiskonen JT, Bowden TA, Crispin M.

Methods Mol Biol. 2015;1331:93-121. doi: 10.1007/978-1-4939-2874-3_7.

14.

Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies.

Pritchard LK, Spencer DI, Royle L, Bonomelli C, Seabright GE, Behrens AJ, Kulp DW, Menis S, Krumm SA, Dunlop DC, Crispin DJ, Bowden TA, Scanlan CN, Ward AB, Schief WR, Doores KJ, Crispin M.

Nat Commun. 2015 Jun 24;6:7479. doi: 10.1038/ncomms8479.

15.

Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope.

Pritchard LK, Harvey DJ, Bonomelli C, Crispin M, Doores KJ.

J Virol. 2015 Sep;89(17):8932-44. doi: 10.1128/JVI.01190-15. Epub 2015 Jun 17.

16.

Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers.

Pritchard LK, Vasiljevic S, Ozorowski G, Seabright GE, Cupo A, Ringe R, Kim HJ, Sanders RW, Doores KJ, Burton DR, Wilson IA, Ward AB, Moore JP, Crispin M.

Cell Rep. 2015 Jun 16;11(10):1604-13. doi: 10.1016/j.celrep.2015.05.017. Epub 2015 Jun 4.

17.

Correction for Doores et al., Two Classes of Broadly Neutralizing Antibodies within a Single Lineage Directed to the High-Mannose Patch of HIV Envelope.

Doores KJ, Kong L, Krumm SA, Le KM, Sok D, Laserson U, Garces F, Poignard P, Wilson IA, Burton DR.

J Virol. 2015 Jun;89(12):6525. doi: 10.1128/JVI.00593-15. No abstract available.

18.

Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance.

Pritchard LK, Spencer DI, Royle L, Vasiljevic S, Krumm SA, Doores KJ, Crispin M.

J Virol. 2015 Jul;89(13):6952-9. doi: 10.1128/JVI.00230-15. Epub 2015 Apr 15.

19.

Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design.

Crispin M, Doores KJ.

Curr Opin Virol. 2015 Apr;11:63-9. doi: 10.1016/j.coviro.2015.02.002. Epub 2015 Mar 6. Review.

20.

Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope.

Doores KJ, Kong L, Krumm SA, Le KM, Sok D, Laserson U, Garces F, Poignard P, Wilson IA, Burton DR.

J Virol. 2015 Jan 15;89(2):1105-18. doi: 10.1128/JVI.02905-14. Epub 2014 Nov 5. Erratum in: J Virol. 2015 Jun;89(12):6525.

21.

Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV.

Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, Kulp DW, Julien JP, Menis S, Wickramasinghe L, Seaman MS, Schief WR, Wilson IA, Poignard P, Burton DR.

Sci Transl Med. 2014 May 14;6(236):236ra63. doi: 10.1126/scitranslmed.3008104.

22.

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.

Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang CH, Mcbride R, von Bredow B, Shivatare SS, Wu CY, Chan-Hui PY, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong CH, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR.

Immunity. 2014 May 15;40(5):657-68. doi: 10.1016/j.immuni.2014.04.009. Epub 2014 Apr 24.

23.

B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates.

Ota T, Doyle-Cooper C, Cooper AB, Doores KJ, Aoki-Ota M, Le K, Schief WR, Wyatt RT, Burton DR, Nemazee D.

J Immunol. 2013 Sep 15;191(6):3179-85. doi: 10.4049/jimmunol.1301283. Epub 2013 Aug 12.

24.

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.

Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA.

Nat Struct Mol Biol. 2013 Jul;20(7):796-803. doi: 10.1038/nsmb.2594. Epub 2013 May 26.

25.

Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans.

Julien JP, Sok D, Khayat R, Lee JH, Doores KJ, Walker LM, Ramos A, Diwanji DC, Pejchal R, Cupo A, Katpally U, Depetris RS, Stanfield RL, McBride R, Marozsan AJ, Paulson JC, Sanders RW, Moore JP, Burton DR, Poignard P, Ward AB, Wilson IA.

PLoS Pathog. 2013;9(5):e1003342. doi: 10.1371/journal.ppat.1003342. Epub 2013 May 2.

26.

2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.

Doores KJ, Huber M, Le KM, Wang SK, Doyle-Cooper C, Cooper A, Pantophlet R, Wong CH, Nemazee D, Burton DR.

J Virol. 2013 Feb;87(4):2234-41. doi: 10.1128/JVI.02820-12. Epub 2012 Dec 5.

27.

Anti-HIV B Cell lines as candidate vaccine biosensors.

Ota T, Doyle-Cooper C, Cooper AB, Huber M, Falkowska E, Doores KJ, Hangartner L, Le K, Sok D, Jardine J, Lifson J, Wu X, Mascola JR, Poignard P, Binley JM, Chakrabarti BK, Schief WR, Wyatt RT, Burton DR, Nemazee D.

J Immunol. 2012 Nov 15;189(10):4816-24. doi: 10.4049/jimmunol.1202165. Epub 2012 Oct 12.

28.

A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.

Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA.

Science. 2011 Nov 25;334(6059):1097-103. doi: 10.1126/science.1213256. Epub 2011 Oct 13.

29.

The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade.

Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, Burton DR, Crispin M, Scanlan CN.

PLoS One. 2011;6(8):e23521. doi: 10.1371/journal.pone.0023521. Epub 2011 Aug 16.

30.

Broad neutralization coverage of HIV by multiple highly potent antibodies.

Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD; Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P.

Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.

31.

Site-selective traceless Staudinger ligation for glycoprotein synthesis reveals scope and limitations.

Bernardes GJ, Linderoth L, Doores KJ, Boutureira O, Davis BG.

Chembiochem. 2011 Jun 14;12(9):1383-6. doi: 10.1002/cbic.201100125. Epub 2011 May 19. No abstract available.

PMID:
21598371
32.

Analysis of the dispersity in carbohydrate loading of synthetic glycoproteins using MALDI-TOF mass spectrometry.

Patel MK, Vijayakrishnan B, Koeppe JR, Chalker JM, Doores KJ, Davis BG.

Chem Commun (Camb). 2010 Dec 28;46(48):9119-21. doi: 10.1039/c0cc03420g. Epub 2010 Oct 29.

PMID:
21038043
33.

A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity.

Doores KJ, Fulton Z, Hong V, Patel MK, Scanlan CN, Wormald MR, Finn MG, Burton DR, Wilson IA, Davis BG.

Proc Natl Acad Sci U S A. 2010 Oct 5;107(40):17107-12. doi: 10.1073/pnas.1002717107. Epub 2010 Sep 17.

34.

Very few substitutions in a germ line antibody are required to initiate significant domain exchange.

Huber M, Le KM, Doores KJ, Fulton Z, Stanfield RL, Wilson IA, Burton DR.

J Virol. 2010 Oct;84(20):10700-7. doi: 10.1128/JVI.01111-10. Epub 2010 Aug 11.

35.

Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.

Doores KJ, Fulton Z, Huber M, Wilson IA, Burton DR.

J Virol. 2010 Oct;84(20):10690-9. doi: 10.1128/JVI.01110-10. Epub 2010 Aug 11.

36.

Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.

Doores KJ, Burton DR.

J Virol. 2010 Oct;84(20):10510-21. doi: 10.1128/JVI.00552-10. Epub 2010 Aug 4.

37.

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, Burton DR, Crispin M, Scanlan CN.

Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13800-5. doi: 10.1073/pnas.1006498107. Epub 2010 Jul 19.

38.

Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds.

Astronomo RD, Kaltgrad E, Udit AK, Wang SK, Doores KJ, Huang CY, Pantophlet R, Paulson JC, Wong CH, Finn MG, Burton DR.

Chem Biol. 2010 Apr 23;17(4):357-70. doi: 10.1016/j.chembiol.2010.03.012.

39.

Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans.

Dunlop DC, Bonomelli C, Mansab F, Vasiljevic S, Doores KJ, Wormald MR, Palma AS, Feizi T, Harvey DJ, Dwek RA, Crispin M, Scanlan CN.

Glycobiology. 2010 Jul;20(7):812-23. doi: 10.1093/glycob/cwq020. Epub 2010 Feb 24.

40.

Rewritable glycochips.

Harris LG, Schofield WC, Doores KJ, Davis BG, Badyal JP.

J Am Chem Soc. 2009 Jun 10;131(22):7755-61. doi: 10.1021/ja901294r.

PMID:
19438244
41.

Reagent switchable stereoselective beta(1,2) mannoside mannosylation: OH-2 of mannose is a privileged acceptor.

Doores KJ, Davis BG.

Org Biomol Chem. 2008 Aug 7;6(15):2692-6. doi: 10.1039/b803999m. Epub 2008 Jun 2.

PMID:
18633526
42.

Atomic-scale detection of organic molecules coupled to single-walled carbon nanotubes.

Hong SY, Tobias G, Ballesteros B, El Oualid F, Errey JC, Doores KJ, Kirkland AI, Nellist PD, Green ML, Davis BG.

J Am Chem Soc. 2007 Sep 12;129(36):10966-7. Epub 2007 Aug 16. No abstract available.

PMID:
17696530
43.

Direct deprotected glycosyl-asparagine ligation.

Doores KJ, Mimura Y, Dwek RA, Rudd PM, Elliott T, Davis BG.

Chem Commun (Camb). 2006 Apr 7;(13):1401-3. Epub 2006 Mar 6.

PMID:
16550280
44.

Exploring and exploiting the therapeutic potential of glycoconjugates.

Doores KJ, Gamblin DP, Davis BG.

Chemistry. 2006 Jan 11;12(3):656-65. Review.

PMID:
16187378
45.

Ligand amplification in a dynamic combinatorial glycopeptide library.

Hotchkiss T, Kramer HB, Doores KJ, Gamblin DP, Oldham NJ, Davis BG.

Chem Commun (Camb). 2005 Sep 14;(34):4264-6. Epub 2005 Aug 9. Erratum in: Chem Commun (Camb). 2006 Sep 21;(35):3741.

PMID:
16113716
46.

"Polar patch" proteases as glycopeptiligases.

Doores KJ, Davis BG.

Chem Commun (Camb). 2005 Jan 14;(2):168-70. Epub 2004 Dec 3.

PMID:
15724174

Supplemental Content

Loading ...
Support Center